deaths (OS)progression or deaths (PFS)RFS/DFS

la/mBC - HER2 positive - 1st Line (L1) breast cancer - HER2-positive la/mBC - HER2 positive la/mBC - HER2 positive - 1st Line (L1)

versus trastuzumab plus docetaxel
bevacizumab plus trastuzumab plus docetaxel vs. trastuzumab plus docetaxel 1 certainty unassessable-6% certainty unassessable-17%-